Jasper Therapeutics (NASDAQ:JSPR) Receives “Market Outperform” Rating from JMP Securities

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “market outperform” rating reiterated by investment analysts at JMP Securities in a report issued on Monday,Benzinga reports. They presently have a $70.00 price target on the stock. JMP Securities’ price objective indicates a potential upside of 263.26% from the stock’s current price.

Other analysts also recently issued research reports about the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $68.00 target price on shares of Jasper Therapeutics in a research report on Monday, December 23rd. HC Wainwright reiterated a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. BMO Capital Markets started coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $73.38.

Jasper Therapeutics Trading Down 8.6 %

Jasper Therapeutics stock opened at $19.27 on Monday. Jasper Therapeutics has a 1-year low of $6.50 and a 1-year high of $31.01. The company has a fifty day simple moving average of $22.07 and a 200 day simple moving average of $20.50. The company has a market cap of $289.07 million, a P/E ratio of -4.07 and a beta of 2.18.

Hedge Funds Weigh In On Jasper Therapeutics

Several large investors have recently modified their holdings of the stock. Samsara BioCapital LLC raised its holdings in Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after acquiring an additional 59,642 shares during the period. Braidwell LP acquired a new position in shares of Jasper Therapeutics in the third quarter valued at approximately $9,091,000. Ally Bridge Group NY LLC increased its stake in shares of Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after purchasing an additional 180,852 shares during the period. State Street Corp lifted its holdings in Jasper Therapeutics by 12.3% during the 3rd quarter. State Street Corp now owns 214,883 shares of the company’s stock worth $4,042,000 after purchasing an additional 23,564 shares during the last quarter. Finally, Fernwood Investment Management LLC boosted its stake in Jasper Therapeutics by 6.9% in the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock valued at $995,000 after purchasing an additional 3,427 shares during the period. 79.85% of the stock is owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.